Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
24 4월 2024 - 11:00PM
Business Wire
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing
novel immunological agents to treat various cancers, today
announced an upcoming presentation from the Phase 1b trial of
botensilimab in combination with balstilimab (“BOT/BAL”) in
patients with relapsed/refractory microsatellite stable colorectal
cancer with no active liver metastases (r/r MSS CRC NLM) will be
presented at the upcoming American Society of Clinical Oncology
(ASCO) Meeting, to be held May 31 – June 4, 2024, in Chicago, IL.
The poster presentation is for a sub-analysis of the r/r MSS CRC
cohort of the Phase 1b study. This sub-analysis was done to
determine whether treatment outcomes are correlated with specific
sites of metastatic disease in patients with non-active liver
mets.
Presentation Details:
Abstract Title: Botensilimab plus balstilimab in
microsatellite stable metastatic colorectal cancer: Assessing
efficacy in non-liver metastatic sites.
Abstract Number: 3556
Presenting Author: Marwan Fakih, MD, Division Head, GI
Medical Oncology, City of Hope Comprehensive Cancer Center
Session: Poster Session – Gastrointestinal Cancer –
Colorectal and Anal
Session Date and Time: June 1, 2024, at 1:30 p.m. – 4:30
p.m. CT
Complete abstracts will be released Thursday, May 23, 2024, at
5:00 p.m. ET. Data presented at the conference will be available to
view in the publications section of the Agenus website
(https://agenusbio.com/publications) following the ASCO
Meeting.
About Botensilimab
Botensilimab is an investigational multifunctional anti-CTLA-4
immune activator (antibody) designed to boost both innate and
adaptive anti-tumor immune responses. Its novel design leverages
mechanisms of action to extend immunotherapy benefits to "cold"
tumors which generally respond poorly to standard of care or are
refractory to conventional PD-1/CTLA-4 therapies and
investigational therapies. Botensilimab augments immune responses
across a wide range of tumor types by priming and activating T
cells, downregulating intratumoral regulatory T cells, activating
myeloid cells and inducing long-term memory responses.
Approximately 900 patients have been treated with botensilimab
in phase 1 and phase 2 clinical trials. Botensilimab alone, or in
combination with Agenus’ investigational PD-1 antibody,
balstilimab, has shown clinical responses across nine metastatic,
late-line cancers. For more information about botensilimab trials,
visit www.clinicaltrials.gov with the identifiers NCT03860272,
NCT05608044, NCT05630183, and NCT05529316.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and
infectious diseases with a comprehensive pipeline of immunological
agents. The company’s mission is to expand patient populations
benefiting from cancer immunotherapy through combination
approaches, using a broad repertoire of antibody therapeutics,
adoptive cell therapies (through MiNK Therapeutics) and adjuvants
(through SaponiQx). Agenus is headquartered in Lexington, MA. For
more information, visit www.agenusbio.com or @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and social media channels.
Forward-Looking
Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding a its botensilimab
and balstilimab programs, expected regulatory timelines and
filings, and any other statements containing the words "may,"
"believes," "expects," "anticipates," "hopes," "intends," "plans,"
"forecasts," "estimates," "will," “establish,” “potential,”
“superiority,” “best in class,” and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Annual Report on
Form 10-K for 2022, and subsequent Quarterly Reports on Form 10-Q
filed with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240424486771/en/
Investors 917-362-1370
investor@agenusbio.com Media
917-362-1370 communications@agenusbio.com
Agenus (NASDAQ:AGEN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Agenus (NASDAQ:AGEN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024